The economic impact of epilepsy: a systematic review

Katharina Allers, Beverley M Essue, Maree L Hackett, Janani Muhunthan, Craig S Anderson, Kristen Pickles, Franziska Scheibe, Stephen Jan, Katharina Allers, Beverley M Essue, Maree L Hackett, Janani Muhunthan, Craig S Anderson, Kristen Pickles, Franziska Scheibe, Stephen Jan

Abstract

Background: In this review we aimed to determine the economic impact of epilepsy and factors associated with costs to individuals and health systems.

Methods: A narrative systematic review of incidence and case series studies with prospective consecutive patient recruitment and economic outcomes published before July 2014 were retrieved from Medline, Embase and PsycInfo.

Results: Of 322 studies reviewed, 22 studies met the inclusion criteria and 14 were from high income country settings. The total costs associated with epilepsy varied significantly in relation to the duration and severity of the condition, response to treatment, and health care setting. Where assessed, 'out of pocket' costs and productivity losses were found to create substantial burden on households which may be offset by health insurance. However, populations covered ostensibly for the upfront costs of care can still bear a significant economic burden.

Conclusions: Epilepsy poses a substantial economic burden for health systems and individuals and their families. There is uncertainty over the degree to which private health insurance or social health insurance coverage provides adequate protection from the costs of epilepsy. Future research is required to examine the role of different models of care and insurance programs in protecting against economic hardship for this condition, particularly in low and middle income settings.

Figures

Fig. 1
Fig. 1
PRISMA Flowchart of included and excluded studies

References

    1. Kotsopoulos IA, Van Merode T, Kessels FG, De Krom MC, Knottnerus JA. Systematic Review and Meta‐analysis of Incidence Studies of Epilepsy and Unprovoked Seizures. Epilepsia. 2002;43(11):1402–1409. doi: 10.1046/j.1528-1157.2002.t01-1-26901.x.
    1. Sander J, Shorvon S. Incidence and prevalence studies in epilepsy and their methodological problems: a review. J Neurol Neurosurg Psychiatry. 1987;50(7):829–839. doi: 10.1136/jnnp.50.7.829.
    1. Forsgren I, Beghi E, Ekman M. Cost of epilepsy in Europe. Eur J Neurol. 2005;12(s1):54–58. doi: 10.1111/j.1468-1331.2005.01191.x.
    1. Cockerell OC, Hart YM, Sander JW, Shorvon SD. The cost of epilepsy in the United Kingdom: an estimation based on the results of two population-based studies. Epilepsy Res. 1994;18(3):249–260. doi: 10.1016/0920-1211(94)90045-0.
    1. Hackett ML, Glozier NS, Martiniuk AL, Jan S, Anderson CS. Sydney epilepsy incidence study to measure illness consequences: the SESIMIC observational epilepsy study protocol. BMC Neurol. 2011;11(1):3. doi: 10.1186/1471-2377-11-3.
    1. Strzelczyk A, Reese JP, Dodel R, Hamer HM. Cost of epilepsy: a systematic review. Pharmacoeconomics. 2008;26(6):463–476. doi: 10.2165/00019053-200826060-00002.
    1. Pugliatti M, Beghi E, Forsgren L, Ekman M, Sobocki P. Estimating the cost of epilepsy in Europe: a review with economic modeling. Epilepsia. 2007;48(12):2224–2233.
    1. Beghi E, Frigeni B, Beghi M, De Compadri P, Garattini L. A review of the costs of managing childhood epilepsy. PharmacoEconomics. 2005;23(1):27–45. doi: 10.2165/00019053-200523010-00003.
    1. Begley CE, Beghi E. The economic cost of epilepsy: a review of the literature. Epilepsia. 2002;43(s4):3–9. doi: 10.1046/j.1528-1157.43.s.4.2.x.
    1. Brunetti M, Pagano E, Garattini L. The economic cost of epilepsy: a review. Ital J Neurol Sci. 1998;19(2):116–119. doi: 10.1007/BF02427569.
    1. Ekman M, Forsgren L. Economic evidence in epilepsy: a review. Eur J Health Econ. 2004;5:s36–s42. doi: 10.1007/s10198-005-0287-0.
    1. Fisher RS, Boas WE, Blume W, Elger C, Genton P, Lee P, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE) Epilepsia. 2005;46(4):470–472. doi: 10.1111/j.0013-9580.2005.66104.x.
    1. The Joanna Briggs Institute. Joanna Briggs Institute Reviewers’ Manual: 2011 Edition. Appendix VII - MAStARI critical appraisal tools. 2011. . Accessed 22 December 2014.
    1. Beghi E, Garattini L, Ricci E, Cornago D, Parazzini F. Direct Cost of Medical Management of Epilepsy among Adults in Italy: A Prospective Cost-of-Illness Study (EPICOS) Epilepsia. 2004;45(2):171–178. doi: 10.1111/j.0013-9580.2004.14103.x.
    1. Boon P, D’Have M, Van Walleghem P, Michielsen G, Vonck K, Caemaert J, et al. Direct medical costs of refractory epilepsy incurred by three different treatment modalities: A prospective assessment. Epilepsia. 2002;43(1):96–102. doi: 10.1046/j.1528-1157.2002.40100.x.
    1. Guerrini R, Battini R, Ferrari A, Veggiotti P, Besana D, Gobbi G, et al. The costs of childhood epilepsy in Italy: comparative findings from three health care settings. Epilepsia. 2001;42(5):641–646. doi: 10.1046/j.1528-1157.2001.27300.x.
    1. Kotsopoulos IA, Evers SM, Ament AJ, Kessels FG, de Krom MC, Twellaar M, et al. The costs of epilepsy in three different populations of patients with epilepsy. Epilepsy Res. 2003;54(2):131–140. doi: 10.1016/S0920-1211(03)00062-7.
    1. Langfitt J, Holloway R, McDermott M, Messing S, Sarosky K, Berg A, et al. Health care costs decline after successful epilepsy surgery. Neurology. 2007;68(16):1290–1298. doi: 10.1212/01.wnl.0000259550.87773.3d.
    1. Tetto A, Manzoni P, Millul A, Beghi E, Garattini L, Tartara A, et al. The costs of epilepsy in Italy: A prospective cost-of-illness study in referral patients with disease of different severity. Epilepsy Res. 2002;48(3):207–216. doi: 10.1016/S0920-1211(02)00013-X.
    1. De Zelicourt M, Buteau L, Fagnani F, Jallon P. The contributing factors to medical cost of epilepsy: An estimation based on a French prospective cohort study of patients with newly diagnosed epileptic seizures (the CAROLE study) Seizure. 2000;9(2):88–95. doi: 10.1053/seiz.1999.0364.
    1. Lindsten H, Stenlund H, Edlund C, Forsgren L. Socioeconomic Prognosis after a Newly Diagnosed Unprovoked Epileptic Seizure in Adults: A Population‐based Case–Control Study. Epilepsia. 2002;43(10):1239–1250. doi: 10.1046/j.1528-1157.2002.51101.x.
    1. Pato Pato A, Cebrian Perez E, Cimas Hernando I, Lorenzo Gonzalez JR, Rodriguez Constenla I, Gude SF. Analysis of direct, indirect, and intangible costs of epilepsy. Neurologia. 2011;26(1):32–38. doi: 10.1016/j.nrl.2010.10.002.
    1. Strzelczyk A, Haag A, Reese JP, Nickolay T, Oertel WH, Dodel R, et al. Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany. Epilepsy Behav. 2013;27(3):433–438. doi: 10.1016/j.yebeh.2013.03.007.
    1. Balabanov PP, Zahariev ZI, Mateva NG. Evaluation of the factors affecting the quality of life and total costs in epilepsy patients on monotherapy with carbamazepine and valproate. Folia Med. 2007;50(2):18–23.
    1. Das K, Banerjee M, Mondal G, Devi LG, Singh O, Mukherjee B. Evaluation of socio-economic factors causing discontinuation of epilepsy treatment resulting in seizure recurrence: a study in an urban epilepsy clinic in India. Seizure. 2007;16(7):601–607. doi: 10.1016/j.seizure.2007.04.008.
    1. Farmer P, Placencia M, Jumbo L, Sander J, Shorvon S. Effects of epilepsy on daily functioning in northern Ecuador: summary of findings of a population-based research project. Neuroepidemiology. 1992;11(4–6):180–189. doi: 10.1159/000110930.
    1. Vlasov PN, Orekhova NV. The cost-benefit analysis of new antiepileptic drugs. Zhurnal Nevrologii I Psihiatrii imeni S.S. Korsakova. 2010;111(10):39–43.
    1. Lv R, Wu L, Jin L, Lu Q, Wang M, Qu Y, et al. Depression, anxiety and quality of life in parents of children with epilepsy. Acta Neurol Scand. 2009;120(5):335–341. doi: 10.1111/j.1600-0404.2009.01184.x.
    1. Haroon A, Tripathi M, Khanam R, Vohora D. Antiepileptic drugs prescription utilization behaviour and direct costs of treatment in a national hospital of India. Ann Indian Acad Neurol. 2012;15(4):289. doi: 10.4103/0972-2327.104338.
    1. Dongmo L, Echouffo B, Njamnshi A, Kamdem P, Sini V, Pepouomi M. Difficulties faced in the management of epilepsy in rural Cameroon: the case of Mbangassina locality. Afr J Neurol Sci. 2003;22(1).
    1. Doumbia-Ouattara M, Yapo F, Kouassi L, Kouame-assouan AE, Aka-Diarra E, Sonan-Douayoua T. Evaluation of the treatment of adults epileptic inpatients in the Department of Neurology at Teaching Hospital of Yopougon Abidjan-Cote d’I’voire. Afr J Neurol Sci. 2010;29(1).
    1. Lagunju I, Imam Z, Adedokun B. Cost of epilepsy in children attending a tertiary centre in Nigeria. International Health. 2011;3(3):213–218. doi: 10.1016/j.inhe.2011.07.001.
    1. Helmstaedter C, Kurthen M, Lux S, Johanson K, Quiske A, Schramm J, et al. Temporal lobe epilepsy: longitudinal clinical, neuropsychological and psychosocial follow-up of surgically and conservatively managed patients. Nervenarzt. 2000;71(8):629–42. doi: 10.1007/s001150050639.
    1. Halpern MT, Renaud JM, Vickrey BG. Impact of insurance status on access to care and out-of-pocket costs for US individuals with epilepsy. Epilepsy Behav. 2011;22(3):483–9. doi: 10.1016/j.yebeh.2011.07.007.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir